Journal article
Abstract PO4-13-01: A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes
Abstract
Abstract Background: While adjuvant 6-monthly zoledronate is widely used in patients with early-stage breast cancer (EBC), questions remain around optimal scheduling of adjuvant bisphosphonates. We reviewed quality of life and bisphosphonate-related toxicities observed within a prospective randomised trial. Methods: Patients with EBC were randomised to either a single infusion of adjuvant zoledronate (4mg IV) or to 6-monthly treatment for 3 …
Authors
Machado I; Clemons L; Stober C; Pond G; Awan A; Conter H; Simos D; Dhesy-Thind S; Mates M; Kumar V
Journal
Cancer Research, Vol. 84, No. 9_Supplement,
Publisher
American Association for Cancer Research (AACR)
Publication Date
May 2, 2024
DOI
10.1158/1538-7445.sabcs23-po4-13-01
ISSN
0008-5472